Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease
about
Developing stem cell therapies for juvenile and adult-onset Huntington's diseaseThe choreography of neuroinflammation in Huntington's diseaseTransgenic animal models for study of the pathogenesis of Huntington's disease and therapyThe N17 domain mitigates nuclear toxicity in a novel zebrafish Huntington's disease model.N17 Modifies mutant Huntingtin nuclear pathogenesis and severity of disease in HD BAC transgenic miceEffects of deletion of mutant huntingtin in steroidogenic factor 1 neurons on the psychiatric and metabolic phenotype in the BACHD mouse model of Huntington diseaseHuntingtin is required for normal excitatory synapse development in cortical and striatal circuitsA scFv antibody targeting common oligomeric epitope has potential for treating several amyloidoses.Microglial Activation in the Pathogenesis of Huntington's Disease.Targets for future clinical trials in Huntington's disease: what's in the pipeline?Cortical efferents lacking mutant huntingtin improve striatal neuronal activity and behavior in a conditional mouse model of Huntington's diseaseA striatal-enriched intronic GPCR modulates huntingtin levels and toxicityAltered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington's disease.Probing the stress and depression circuits with a disease gene.Selective vulnerability of Rich Club brain regions is an organizational principle of structural connectivity loss in Huntington's disease.A role for Kalirin-7 in corticostriatal synaptic dysfunction in Huntington's diseaseEnhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model.Quantitative Electroencephalographic Analysis Provides an Early-Stage Indicator of Disease Onset and Progression in the zQ175 Knock-In Mouse Model of Huntington's Disease.Widespread Central Nervous System Gene Transfer and Silencing After Systemic Delivery of Novel AAV-AS Vector.Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington's disease.PIAS1 Regulates Mutant Huntingtin Accumulation and Huntington's Disease-Associated Phenotypes In VivoTRiC subunits enhance BDNF axonal transport and rescue striatal atrophy in Huntington's diseasePreclinical models: needed in translation? A Pro/Con debate.Evidence to support mitochondrial neuroprotection, in severe traumatic brain injury.Allele-selective suppression of mutant genes in polyglutamine diseases.Viral vectors for therapy of neurologic diseases.Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington's disease.Cognitive dysfunction in Huntington's disease: mechanisms and therapeutic strategies beyond BDNF.Dysregulation of Corticostriatal Connectivity in Huntington's Disease: A Role for Dopamine ModulationHuntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics.Differential electrophysiological and morphological alterations of thalamostriatal and corticostriatal projections in the R6/2 mouse model of Huntington's disease.Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice.Allele-Specific Reduction of the Mutant Huntingtin Allele Using Transcription Activator-Like Effectors in Human Huntington's Disease Fibroblasts.Something wicked this way comes: huntingtin.Therapies targeting DNA and RNA in Huntington's disease.Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice.The Evidence for the Spread and Seeding Capacities of the Mutant Huntingtin Protein in in Vitro Systems and Their Therapeutic Implications.Cdk5 Contributes to Huntington's Disease Learning and Memory Deficits via Modulation of Brain Region-Specific Substrates.Meta-analytic evaluation of the association between head injury and risk of amyotrophic lateral sclerosis.Molecular insights into cortico-striatal miscommunications in Huntington's disease.
P2860
Q26799722-D97D34F2-7209-4986-A1D5-266E0CD6FFA3Q26828403-856DE564-1FC4-4C34-8F2B-A50A3E6B8B9DQ26849677-739D09F1-4C2A-4FD7-AFBD-643889A529B4Q27301298-800EB015-B23F-4EFF-BE8A-49FB9E433104Q27306025-E8C089D5-1646-44BE-8A8D-7376F62C7467Q27346849-9682B7EA-4E39-462D-83C1-16919910A88DQ30408636-0DCD0CEF-5569-48EF-A3CD-FBACFF47BC0FQ30827953-9F811531-1A87-42CA-B542-5D1BDB673281Q33809556-20BA7D62-9518-4133-98D8-1CF56A89A958Q34435001-56710C38-C443-4959-8D4B-C79C9137CCD8Q35164101-6F54A1C0-5DB9-40FB-97D7-178AB380501CQ35214858-D6B28E78-0A5B-473C-88E1-82D8D0AC52E9Q35560350-904D068A-F310-4C92-819F-B99945E11492Q36059819-BEA698C9-6A37-4BDF-8AE5-18088320E129Q36206024-3E27C00A-7F39-48C1-B789-6365E74B4C98Q36331582-BDEBCE8F-724F-4DE2-8A41-83487E44394EQ36431970-E93714C8-0841-4887-ADB3-64CB80B4AABBQ36461072-9CD4D328-3BF3-41B0-AD0F-337D714920EFQ36951265-CB90CC38-A6A5-4B6E-A222-2BD51C09191FQ37051728-06F331D9-BE5C-41CD-A8BB-012C7A4FD692Q37088539-AAE62F68-113B-48DE-9A92-D6BF60322F86Q37281403-55702B22-006E-4466-9204-6CC38F1EBF4CQ38248688-AF38EA63-B82E-45B0-9FB0-93A08EA4021EQ38263989-74324003-ACE4-46C6-97A3-899828680498Q38547027-6C47B98F-7588-431B-ADF8-2B3DC126C56EQ38746238-84CA7DAB-F5D7-4EA0-86CE-A07EBE85660CQ38925490-CF1933B6-04C5-49CD-99D8-99A73B60AA35Q38928777-4EB06DAD-972F-409F-B4BE-5FB7463F4AEEQ39041217-2626B539-E63F-4515-B577-23F6885FB679Q39165036-7137C633-E5B8-4473-9E25-84104D759D71Q40102175-AFDADFEE-BDF9-4A10-BC10-6BC29A139CEBQ40558924-6842A400-E287-450B-B0CB-6BCCD2B7202BQ45138428-50A4E2E6-0A83-4B3F-893F-C3BAF9EBCD75Q45300759-09F2B5A3-0CDC-41EB-AD0E-1411DF3135D7Q45304275-F3BB791D-0B7D-42A3-A1F6-05C69F3F9FDCQ46306829-ADC3412E-4CA3-4064-B296-BBD8CFE386E4Q47102449-77973378-C664-437D-BDC9-794F554883D6Q47890221-9C44A81E-3087-47F9-BAE9-4E921A57A07BQ48110461-D1705906-198A-48F2-B0B9-874CBC91BCFEQ50069504-953E1F4C-230F-46B1-96DD-4AB1188FE469
P2860
Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Neuronal targets for reducing ...... model of Huntington's disease
@ast
Neuronal targets for reducing ...... model of Huntington's disease
@en
type
label
Neuronal targets for reducing ...... model of Huntington's disease
@ast
Neuronal targets for reducing ...... model of Huntington's disease
@en
prefLabel
Neuronal targets for reducing ...... model of Huntington's disease
@ast
Neuronal targets for reducing ...... model of Huntington's disease
@en
P2093
P2860
P356
P1433
P1476
Neuronal targets for reducing ...... model of Huntington's disease
@en
P2093
Carlos Cepeda
Dyna Shirasaki
Erin Greiner
Hongwei Dong
Jeffrey P Cantle
Michael S Levine
Michelle Gray
Sandra M Holley
X William Yang
P2860
P2888
P304
P356
10.1038/NM.3514
P407
P50
P577
2014-04-28T00:00:00Z